Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.45 |
| ▸ | ARG2 | P78540 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818499 | 1.00 | ARG1 (0.45) | ARG1ARG2POLBGBA1SLC1A2 | |
| SCHEMBL11285029 | 0.89 | POLB (0.57) | ARG1POLBGBA1 | |
| SCHEMBL31080858 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080905 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080989 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1818043 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080883 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1820924 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1816822 | 0.85 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL2510006 | 0.85 | ARG1 (0.42) | ARG1ARG2POLBSLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-10266566-B2 | Protease-resistant peptide ligands | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160159859-A1 | PROTEASE-RESISTANT PEPTIDE LIGANDS | NORTH CAROLINA STATE UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | ARG1 140/4885ARG2 225/4885POLB 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.